Related Experiment Video

Updated: Jul 15, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy

B Mladosievicova1, A Carter, V Kristova

  • 1Institute of Pathological Physiology, Comenius University, Bratislava, Slovakia. beata.mladosievicova@fmed.uniba.sk

Neoplasma
|April 24, 2007
PubMed

Insights

Standard cancer treatments often fail due to genetic variations. This review explores how genetic differences impact chemotherapy efficacy and toxicity, moving beyond single-gene analysis to polygenic effects.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Genetics

Background:

  • Standard chemotherapy exhibits variable efficacy and toxicity in cancer patients.
  • Current approaches often fail to account for individual genetic differences.
  • Existing pharmacogenetic studies primarily focus on single-gene variations and drug toxicity.

Purpose of the Study:

  • To review genetic variations influencing chemotherapy efficacy and toxicity.
  • To highlight the polygenic nature of drug response in cancer treatment.
  • To discuss limitations of single-enzyme deficiency focus in pharmacogenetics.

Main Methods:

  • Literature review of pharmacogenetic and pharmacogenomic studies.
  • Analysis of gene variations impacting anticancer drug response.
  • Discussion of polygenic inheritance in drug metabolism and efficacy.

Main Results:

  • Genetic variations significantly affect both toxicity and efficacy of chemotherapeutics like 5-fluorouracil and platinum analogues.
  • Focus on single-gene deficiencies is insufficient to predict complex drug responses.
  • Polygenic effects, involving multiple gene products, are crucial for determining drug outcomes.

Conclusions:

  • Personalized cancer therapy requires understanding polygenic influences on drug response.
  • Pharmacogenomic insights are essential for optimizing chemotherapy efficacy and minimizing adverse drug reactions.
  • Future research should address the complex interplay of multiple genes in cancer drug response.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...